Treatment alternatives

The currently licensed glucagon-like peptide-1 (GLP-1) mimetics other than lixisenatide are:

  • exenatide

    • Byetta 5 microgram and 10 microgram solutions for injection in prefilled pens (twice-daily use)

    • Bydureon 2 mg powder and solvent for prolonged-release suspension for injection (once-weekly use)

  • liraglutide

    • Victoza 6 mg/ml solution for injection in prefilled pen (once-daily use).

The Introduction gives details of NICE recommendations on using both exenatide and liraglutide.

Costs of treatment alternatives

Pack sizes differ among the GLP-1 mimetics. Yearly costs have therefore been calculated on the basis of costs per 365 days for medication administered each day and costs per 52 weeks for the once-weekly exenatide formulation.

Drug and usual dosage a

Annual cost

Exenatide 5 micrograms twice daily


Exenatide 10 micrograms twice daily


Exenatide 2 mg once weekly


Liraglutide 1.2 mg once daily


Lixisenatide 20 micrograms once daily


a The doses shown are taken from the relevant summary of product characteristics, but do not represent the full range that can be used nor do they imply therapeutic equivalence. Liraglutide is also licensed at a dose of 1.8 mg once daily but this is not recommended in NICE technology appraisal guidance 203.

b Costs taken from Drug Tariff July 2013.

c Costs excluding VAT, taken from MIMS July 2013.